Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial

医学 慢性阻塞性肺病 哮喘 内科学 安慰剂 养生 临床终点 临床试验 物理疗法 病理 替代医学
作者
Klaus F. Rabe,Bartolomé R. Celli,Michael E. Wechsler,Raolat M. Abdulai,Xiaodong Luo,Maarten M. Boomsma,Heribert Staudinger,Julie Horowitz,Aris Baras,Manuel A. R. Ferreira,Marcella Ruddy,Michael C. Nivens,Nikhil Amin,Wenhui Wei,George D. Yancopoulos,Hélène Goulaouic
出处
期刊:The Lancet Respiratory Medicine [Elsevier]
卷期号:9 (11): 1288-1298 被引量:97
标识
DOI:10.1016/s2213-2600(21)00167-3
摘要

Summary

Background

Genetic data implicate IL-33 in asthma susceptibility. Itepekimab, a monoclonal antibody targeting IL-33, demonstrated clinical activity in asthma, with potential in chronic obstructive pulmonary disease (COPD). In this study we first aimed to test the hypothesis that genetic variants in the IL-33 pathway were also associated with COPD. On the basis of the strong association of IL-33 pathway genes with pulmonary diseases like asthma and COPD, we conducted this phase 2a trial to assess the safety and efficacy of itepekimab in patients with moderate-to-severe COPD on a stable regimen of triple-inhaled or double-inhaled background maintenance therapy.

Methods

In this two-part study, genetic analyses of loss-of-function and gain-of-function variants in the IL-33 pathway, previously associated with asthma risk, were initially characterised for COPD. We then did a double-blind, phase 2a trial comparing itepekimab with placebo in patients with moderate-to-severe COPD despite standard therapy, at 83 study sites in ten countries. Patients aged 40–75 years who were current or former smokers, had been diagnosed with COPD for at least 1 year, and were on a stable regimen of triple-inhaled or double-inhaled background maintenance therapy, were randomly assigned (1:1) to receive itepekimab 300 mg or placebo, administered as two subcutaneous injections every 2 weeks for 24–52 weeks. The primary endpoint of the phase 2a trial was annualised rate of moderate-to-severe acute exacerbations of COPD during the treatment period. The key secondary outcome was change in prebronchodilator FEV1 from baseline to weeks 16–24. Prespecified subgroup analyses were done for each of the endpoints, including by smoking status. Efficacy and safety analyses were done in all participants who received at least one dose of assigned treatment (modified intention-to-treat population). This trial is registered at ClinicalTrials.gov (NCT03546907).

Findings

Genetic analyses demonstrated association of loss of function in IL33 with reduced COPD risk, and gain of function in IL33 and IL1RL1 variants with increased risk. Subsequent to this, in the phase 2 trial, 343 patients were randomly assigned to placebo (n=171) or itepekimab (n=172) from July 16, 2018, to Feb 19, 2020. Annualised rates of acute exacerbations of COPD were 1·61 (95% CI 1·32–1·97) in the placebo group and 1·30 (1·05–1·61) in the itepekimab group (relative risk [RR] 0·81 [95% CI 0·61–1·07], p=0·13), and least squares mean prebronchodilator FEV1 change from baseline to weeks 16–24 was 0·0 L (SD 0·02) and 0·06 L (0·02; difference 0·06 L [95% CI 0·01–0·10], p=0·024). When analysis was restricted to former smokers, treatment with itepekimab was associated with nominally significant reductions in acute exacerbations of COPD (RR 0·58 [95% CI 0·39–0·85], p=0·0061) and FEV1 improvement (least squares mean difference 0·09 L [0·02–0·15], p=0·0076) compared with placebo. Current smokers treated with itepekimab showed no treatment benefit versus placebo for exacerbations (RR 1·09 [0·74–1·61], p=0·65) or FEV1 (least squares mean difference 0·02 [−0·05 to 0·09], p=0·54). Treatment-emergent adverse events (TEAEs) occurred in 135 (78%) patients in the itepekimab group and 136 (80%) in the placebo group. The most common TEAEs were nasopharyngitis (28 [16%] in the itepekimab group vs 29 [17%] in the placebo group), bronchitis (18 [10%] vs 14 [8%]), headache (14 [8%] vs 23 [13%]), and upper respiratory tract infection (13 [8%] vs 15 [9%]).

Interpretation

The primary endpoint in the overall population was not met, subgroup analysis showed that itepekimab reduced exacerbation rate and improved lung function in former smokers with COPD. Two phase 3 clinical studies are ongoing to confirm the efficacy and safety profile of itepekimab in former smokers with COPD.

Funding

Sanofi and Regeneron Pharmaceuticals.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
3秒前
feijelly完成签到 ,获得积分10
3秒前
时鹏飞完成签到 ,获得积分10
11秒前
jiudai完成签到 ,获得积分10
12秒前
无为完成签到 ,获得积分10
16秒前
织心完成签到 ,获得积分10
18秒前
她的城完成签到,获得积分10
18秒前
时尚的梦曼完成签到,获得积分10
18秒前
tonight完成签到 ,获得积分10
19秒前
活泼的似狮完成签到,获得积分10
24秒前
合适醉蝶完成签到 ,获得积分10
26秒前
喜悦香萱完成签到 ,获得积分10
29秒前
41秒前
轻松的孤云完成签到,获得积分10
41秒前
一枝完成签到 ,获得积分10
42秒前
薄荷小新完成签到 ,获得积分10
42秒前
mm发布了新的文献求助10
45秒前
bzdjsmw完成签到 ,获得积分10
47秒前
kysl完成签到,获得积分10
59秒前
wanci应助mm采纳,获得10
1分钟前
Only完成签到 ,获得积分10
1分钟前
风-FBDD完成签到,获得积分10
1分钟前
CWC完成签到,获得积分10
1分钟前
入门的橙橙完成签到 ,获得积分10
1分钟前
马大翔应助你好采纳,获得10
1分钟前
小李完成签到 ,获得积分10
1分钟前
扬帆起航完成签到 ,获得积分10
1分钟前
毛毛弟完成签到 ,获得积分10
1分钟前
倪小呆完成签到 ,获得积分10
1分钟前
化身孤岛的鲸完成签到 ,获得积分10
1分钟前
1分钟前
曾经的采波完成签到 ,获得积分10
1分钟前
Emma完成签到,获得积分10
1分钟前
黑球发布了新的文献求助10
1分钟前
阳光森林完成签到 ,获得积分10
1分钟前
一二完成签到 ,获得积分10
1分钟前
酷波er应助科研通管家采纳,获得10
1分钟前
薰硝壤应助科研通管家采纳,获得10
1分钟前
薰硝壤应助科研通管家采纳,获得10
1分钟前
所所应助科研通管家采纳,获得10
1分钟前
高分求助中
좌파는 어떻게 좌파가 됐나:한국 급진노동운동의 형성과 궤적 2500
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Cognitive linguistics critical concepts in linguistics 800
Threaded Harmony: A Sustainable Approach to Fashion 799
Livre et militantisme : La Cité éditeur 1958-1967 500
氟盐冷却高温堆非能动余热排出性能及安全分析研究 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3052652
求助须知:如何正确求助?哪些是违规求助? 2709891
关于积分的说明 7418319
捐赠科研通 2354494
什么是DOI,文献DOI怎么找? 1246122
科研通“疑难数据库(出版商)”最低求助积分说明 605951
版权声明 595921